National Institute of Environmental Health Sciences; Notice of Closed Meeting, 36240 [E9-17303]
Download as PDF
<![CDATA[
36240
Federal Register / Vol. 74, No. 139 / Wednesday, July 22, 2009 / Notices
jlentini on DSKJ8SOYB1PROD with NOTICES
Licensing Contact: Peter A. Soukas,
J.D.; 301–435–4646;
soukasp@mail.nih.gov.
A Unique Infectious Hepatitis C Virus
Clone, Strain HC–TN (genotype 1a)
Description of Invention: It is
anticipated that this infectious clone of
hepatitis C virus (HCV) strain HC–TN
(genotype 1a) will be useful for the
development of vaccines and antiviral
drugs that target HCV, genotype 1a. The
HC–TN strain is unique because it has
been shown to cause fulminant
hepatitis. To date, only one other HCV
strain, JFH1 (genotype 1b), has been
isolated that is known to cause
fulminant hepatitis. Additionally, little
is known about the etiology of
fulminant hepatitis C disease. Therefore,
the HC–TN strain may be useful as a
tool for studying the etiology of
fulminant hepatitis. This invention
includes the infectious clone,
nucleotide sequences of the clone, and
polypeptides encoded by the HC–TN
clone. Methods are included for
producing attenuated HCV, and for
screening therapeutics against HCV and
developing vaccines and diagnostics.
Apparently, no companies or other
laboratories have this HC–TN strain.
The availability of the pHC–TN clone
will be highly useful to pharmaceutical
companies since no further research is
required for its commercialization into,
e.g., assays for testing antiviral
compounds targeting HCV.
Applications:
• Production of attenuated viruses
and polypeptides.
• HCV vaccines, diagnostics,
therapeutics and screening tool for antiHCV compounds.
Advantages: There is no universally
effective therapy against HCV infection.
This invention enables development of
vaccines, diagnostics and therapeutics
that are specific for the HC–TN strain or
HCV genotype 1a.
Development Status: The technology
is currently in the preclinical stage of
development.
Market: More than 80% of the HCV
infections in North and South America,
Europe, Russia, China, Japan and
Australia are genotype 1. The instant
technology may be transferred through
biological materials licenses for
territories in which no patent rights
exist.
Inventors: Jens Bukh, Robert H.
Purcell, Suzanne U. Emerson, Akito
Sakai, Patrizia Farci (NIAID).
Publication: A Sakai et al. In vivo
study of the HC–TN strain of hepatitis
C virus recovered from a patient with
fulminant hepatitis: RNA transcripts of
a molecular clone (pHC–TN) are
VerDate Nov<24>2008
16:04 Jul 21, 2009
Jkt 217001
infectious in chimpanzees but not in
Huh7.5 cells. J Virol. 2007
July;81(13):7208–7219.
Patent Status: U.S. Patent Application
No. 12/061,504 filed 02 April 2008
(HHS Reference No. E–249–2007/0–US–
01); No foreign rights available.
Licensing Status: Available for
licensing.
Licensing Contact: RC Tang, JD, LLM;
301–435–5031; tangrc@mail.nih.gov.
Dated: July 13, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Transfer, National
Institutes of Health.
[FR Doc. E9–17319 Filed 7–21–09; 8:45 am]
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: July 14, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–17303 Filed 7–21–09; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institutes of Health
Healthcare Infection Control Practices
Advisory Committee (HICPAC)
National Institute of Environmental
Health Sciences; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel. Formative Children’s Center
Review 2.
Date: July 24, 2009.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Plaza Hotel, 10 Thomas
Circle, NW., Washington, DC 20005.
Contact Person: Linda K. Bass, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research and Training, Nat. Institute
Environmental Health Sciences, P. O. Box
12233, MD EC–30, Research Triangle Park,
NC 27709. (919) 541–1307.
malone@niehs.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting for the
aforementioned committee:
Time and Date: 11 a.m.–12 p.m., July 23,
2009.
Place: The teleconference call will
originate at the CDC.
Status: Open to the public. Teleconference
access limited only by availability of
telephone ports. To participate in the
teleconference please dial 1 (800) 779–6036
and enter conference code 6417394.
Purpose: The Committee is charged with
providing advice and guidance to the
Secretary, HHS; the Assistant Secretary for
Health; the Director, CDC; and the Director,
National Center for Preparedness, Detection,
and Control of Infectious Diseases
(NCPDCID), regarding: (1) The practice of
hospital infection control; (2) strategies for
surveillance, prevention, and control of
infections (e.g., nosocomial infections),
antimicrobial resistance, and related events
in settings where healthcare is provided; and
(3) periodic updating of guidelines and other
policy statements regarding prevention of
healthcare-associated infections and
healthcare-related conditions.
Matters To Be Discussed: The agenda will
include a follow up discussion of CDC’s
Interim Guidance for Infection Control for
Care of Patients with Confirmed or Suspected
Novel Influenza A (H1N1) Virus Infection in
a Healthcare Setting.
Agenda items are subject to change as
priorities dictate. This notice is being
published less than 15 days prior to the
meeting due to the public health emergency
declared on April 26, 2009. There is a critical
need for this committee to deliberate and
discuss urgent matters related to the H1N1
virus, and be actively engaged in the national
preparedness and response efforts as dictated
by circumstances and events.
E:\FR\FM\22JYN1.SGM
22JYN1
]]>Agencies
[Federal Register Volume 74, Number 139 (Wednesday, July 22, 2009)]
[Notices]
[Page 36240]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-17303]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Environmental Health Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Environmental Health
Sciences Special Emphasis Panel. Formative Children's Center Review
2.
Date: July 24, 2009.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Washington Plaza Hotel, 10 Thomas Circle, NW.,
Washington, DC 20005.
Contact Person: Linda K. Bass, PhD, Scientific Review
Administrator, Scientific Review Branch, Division of Extramural
Research and Training, Nat. Institute Environmental Health Sciences,
P. O. Box 12233, MD EC-30, Research Triangle Park, NC 27709. (919)
541-1307. malone@niehs.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.115,
Biometry and Risk Estimation--Health Risks from Environmental
Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund Hazardous Substances--Basic
Research and Education; 93.894, Resources and Manpower Development
in the Environmental Health Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114, Applied Toxicological Research
and Testing, National Institutes of Health, HHS)
Dated: July 14, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-17303 Filed 7-21-09; 8:45 am]
BILLING CODE 4140-01-P
